Advertisement

Topics

Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo

13:14 EDT 16 Apr 2019 | 2 Minute Medicine

1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression of dementia among patients with prodromal Alzheimer’s disease. 2. Adverse events were more often noted in the verubecestat groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prodromal Alzheimer’s disease is associated with […]
Source: 2 Minute Medicine

Original Article: Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo

NEXT ARTICLE

More From BioPortfolio on "Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...